Matrix metalloproteinase (MMP) 2, MMP7 and MMP9 are important members of the MMP family. Four polymorphisms in the promoter region of these MMPs, which are MMP2 21306 C>T, MMP2 2735 C>T, MMP7 2181 A>G and MMP9 21562 C>T, have been reported to be functional and may contribute to genetic susceptibility to cancers. However, the associations between these polymorphisms and cancer risk remain inconclusive due to conflicting results from different case-control studies. To better evaluate the role of these polymorphisms in cancer development, we conducted a meta-analysis that included 51 studies, with more than 40 000 subjects. The results showed that under dominant genetic model, MMP2 21306 T was associated with lower susceptibility to lung cancer [odds ratio (OR) 5 0.50, 95% confidence interval (CI) 0.43-0.59, P heterogeneity 5 0.147, I 2 5 44.1%], head and neck cancer (OR 5 0.53, 95% CI 0.41-0.69, P heterogeneity 5 0.974, I 2 5 0.0%) and oesophageal cancer (OR 5 0.67, 95% CI 0.55-0.80, P heterogeneity 5 0.593, I 2 5 0.0%); MMP2-735T was associated with lower risk in lung cancer (OR = 0.65, 95%CI 0.53-0.79, P heterogeneity = 0.42, I 2 = 0.0%) and oesophageal cancer (OR 5 0.84, 95% CI 0.70-0.99, P heterogeneity 5 0.206, I 2 5 37.4%); MMP7 2181 AG and GG genotype carriers had an increased gastric cancer risk (OR 5 1.90, 95% CI 1.43-2.51, P heterogeneity 5 0.992, I 2 5 0.0%) and MMP9 21562 C>T was not associated with cancer risk in the whole group analysis (OR 5 0.99, 95% CI 0.91-1.08, P heterogeneity 5 0.419, I 2 5 3.0%) and subgroup analyses. In all, our meta-analysis suggests that MMP2 21306 C>T, MMP2 2735 C>T and MMP7 2181 A>G may play allele-specific roles in cancer development, while MMP9 21562 C>T may not be a major risk factor for most cancer types. Large case-control studies should be performed to clarify the possible roles of these four polymorphisms in different kinds of cancer in more detail.
Introduction
Matrix metalloproteinases (MMPs) are a large family of extracellular metal-dependent neutral endopeptidases, collectively capable of degrading essentially all extracelluar matrix (ECM) components. MMPs can be divided into five divergent groups depending on their substrate specificity and domain structure. These include collagenases, gelatinases, stromelysins, matrilysins and membrane-type MMPs. MMPs not only play important roles in physiological ECM remodelling, such as tissue regeneration, wound repair and embryo development, but are also involved in pathological conditions, such as arthritis, atherosclerosis and autoimmune blistering disorders of the skin. There is also growing evidence indicating that some MMPs are involved in several steps of cancer development by modulating cell proliferation, apoptosis, angiogenesis, immunosurveillance and so on (1, 2) . MMP2 (gelatinase A or 72-kDa collagenase IV), located on 16q13-q21, is able to degrade gelatin, type IV collagen and some bioactive molecules, such as growth factor-binding proteins and growth factor receptors. In contrast to other MMPs, MMP2 is broadly, often constitutively expressed by a large number of cell types and over-expressed in a wide variety of human cancers, including gastric, lung, prostate, ovarian, oesophageal, oral and bladder cancer (3, 4) . MMP7 (matrilysin, PUMP-1), localised on chromosome 11q21-q22, is among the smallest members of the MMP family, being able to degrade elastin, proteogylcans, fibronectin and type IV collagen. It also cleaves non-matrix substrates from the cell surface, including E-cadherin, pro-tumour necrosis factor and Fas ligand. MMP-7 is primarily expressed in the epithelium of many organs, over-expression of which has been shown to occur in a wide variety of cancers, including tumours of the oesophagus, stomach, colorectal, kidney and breast (5, 6) . MMP9 (gelatinase B), located on chromosome 20q11.2-q13.1, is the most complex family member of MMPs in terms of domain structure, possessing proteolytic activity against type IV collagen, proteoglycan core protein and elastin. MMP9 is expressed in low levels under physiological conditions, but it is increased dramatically in several malignancies including oral, oesophageal, breast, renal, colorectal cancers and melanoma (7) (8) (9) .
Transcriptional regulation is an important mechanism that influences expression levels of these MMPs. Four functional single-nucleotide polymorphisms (SNPs) have been identified in the promoter regions of MMP2, 7 and 9 and have been proved to have allele-specific effects on regulation of MMP gene transcription. They are MMP2 À1306 C.T (rs243865), MMP2 À735 C.T (rs2285053), MMP7 À181 A.G (rs11568818) and MMP9 À1562 C.T (rs3918242) (1, 10, 11) . A large number of molecular epidemiological studies have been performed to evaluate the role of these polymorphisms in various tumours. However, most of these studies only contained small numbers of subjects and they showed conflicting results. In order to better assess the association between these SNPs and cancer risk, we performed a metaanalysis from all eligible case-control studies published to date.
Materials and methods
To identify all potentially eligible studies, two investigators independently conducted key word searches in the PubMed, Embase, EBSCO and Google Scholar. Searches included all possible combinations of selected keywords, including 'carcinoma', 'cancer', 'neoplasm', 'malignancy' or 'tumour' with 'MMP', 'Metalloproteinase', 'collagenase', 'gelatinase', 'matrilysin' or 'PUMP'. References of the retrieved articles and review articles were also screened. Searches were updated as of November 1, 2009 . Eligible studies had to meet all of the following criteria: (i) they were published studies, on at least one of the four functional polymorphisms of MMP2, 7 and 9; (ii) they used an unrelated case-control design and (iii) they applied a useful genotyping method and presented sufficient data to calculate the odds ratio (OR) with a confidence interval (CI) and a P-value.
Data extraction
The following basic data were collected from the studies that could meet the inclusion criteria: first author, tumour type, year of publication, country, ethnicity of study population, number of cases and controls, genotyping method and confirmation of diagnosis. Two independent investigators conducted data extraction work, and they resolved discrepancies through discussion.
Statistical analysis
ORs corresponding to 95% CI were applied to assess the strength of association, according to the method of Woolf (12) . A chi-square-based Q statistical test was performed to assess the between-study heterogeneity (13) . However, as Q test was insensitive in cases where studies were small in size or few in number, I
2 value was also calculated, which represents the percentage of total variation across studies and provides a result of heterogeneity rather than chance. As a guide, I 2 values of ,25% may be considered 'low', values of $50% may be considered 'moderate' and values of .75% may be considered 'high' (14) . If P 0.05, or I 2 ! 50%, a random-effects model using the DerSimonian-Laird method (15) , which yields wider confidence intervals, was adopted, otherwise if P . 0.05, and I 2 ,50%, a fixed-effects model using the Mantel-Haenszel method (16) was used. Furthermore, the variables of tumour sites, ethnicities, control type (diseased or healthy controls), gender type (the subjects were composed by both female and male, only female or male), genotyping method and sample size (subjects .200 in both cases and controls or not) were examined in a metaregression model to explore the possible heterogeneity in between studies. The interstudy variance (s 2 ) was used to quantify the degree of heterogeneity among different studies, and the percentage of s 2 was used to describe the extent of explained heterogeneity of the variables (17) . A Z-test was performed to determine the significance of the pooled OR: a P-value of ,0.05 was considered significant. In this meta-analysis, we examined the association between MMP2 À1306 C.T and cancer risk using three genetic contrasts: recessive genetic model (TT versus TC þ CC), dominant genetic model (TT þ TC versus CC) and allelic contrast (T versus C). The same pattern of method was also applied to analyses of other polymorphisms. In this study, the meta-analysis results were unadjusted. Both Begg's funnel plot (18) and Egger's linear regression test (19) were used to investigate publication bias. Hardy-Weinberg equilibrium (HWE) was tested by comparing the observed and expected genotype frequencies of the controls (v 2 test), at the significant level of a ,0.01. Subgroup analyses stratified by tumour site, ethnicity and smoking status were conducted. If one tumour type contained only one individual study, it was combined into the 'other tumour' subgroup. Ethnicity subgroup analyses were only performed for Asian and European population. Subgroup analyses stratified by smoking status were conducted only under dominant model, with the studies whose stratification data on smoking were available. If possible, the tumour site subgroups with more than three studies were further stratified by ethnicity. As lung, oesophageal, gastric and head and neck cancers are sensitive to similar environment factors, such as smoking and drinking, we also grouped them as upper aerodigestive tract cancers to see whether the association existed in this group. Sensitivity analyses were also applied to assess the stability of the results in the procedure of repeating the metaanalysis by omitting each study one at a time. Haplotype analyses were done with the studies that provided data on MMP2 À1306 C.T and À735 C.T haplotype distributions. All analyses were done with STATA software package v 10.0 (Stata Corporation, College Station, TX, USA). All the P values were two sided.
Results

Study inclusion
A total of 51 published articles (3) (4) (5) (6) (7) (8) (9) (10) (11) , with 74 comparisons, .40 000 subjects, which could meet all of the criteria, were included in this study. Eighteen studies covered two or more polymorphisms (4, 10, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Six studies were published in Chinese (33-38), while the others were published in English. Three studies provided data on MMP2 À1306 C.T and MMP2 À735 C.T haplotype distributions (4, 25, 28) . Two studies (10, 39) , on MMP2 and MMP9, respectively, which did not provide data for all three genotypes but presented genotypes as TT þ TC and CC and reported that genotype distribution in control population was in HWE, were also kept in this study. Zhang investigated three types of cancer in one study (40) . Each type of cancer was treated as a separate study.
Overall, the quality of these included studies was good. In 48 studies (94%), the tumours were histologically or pathologically confirmed. Thirty-nine studies (76%) matched in age, sex and ethnicity in frequency. Forty-six studies (90%) used healthy control samples. The classical genotyping method of polymerase chain reaction-restriction fragment length polymorphism was used in 47 of 74 (64%) comparisons. Supplementary Table S1 , available at Mutagenesis Online shows the descriptive characteristics of these comparisons.
Quantitative synthesis MMP2 À1306 C.T. For MMP2 À1306 C.T, our study contained 26 comparisons with 8297 cases and 10 566 controls. The frequency of MMP2 À1306T allele was significantly lower in the Asian population compared to the European population (Asian: 13.6%, 95% CI 11.5-15.6% and European: 23.3%, 95% CI 16.5-30.0%; P 5 0.0004). In one study (29) , respectively. For all cancer types, the association between MMP2 À1306 T and lower cancer risk was observed under three genetic contrasts and positive associations were maintained in head and neck, lung, gastric and oesophageal cancer subgroups under dominant model. However, no association between MMP2 À1306 C.T and breast cancer or colorectal cancer was found. Further stratified meta-analysis was conducted for lung cancer and the protective effects of MMP2 À1306 T were maintained in Asian population. Subgroup analysis stratified by ethnicity showed that this polymorphism played different roles in Asian and European populations. Asian À1306T carriers were less susceptible to cancers, while in European population, only negative results were found under three genetic contrasts. Subgroup analysis stratified by smoking status showed that MMP2 À1306 C.T was associated with lower cancer risk for both smokers and non-smokers. The analysis for upper aerodigestive tract cancers showed a positive association in three genetic contrasts. More details are shown in Table I and  Figure 1 and supplementary Tables S2 and S3 , available at Mutagenesis Online. Results of sensitive analysis showed that, for all cancers, the results were not excessively influenced by any single study.
MMP2 À735 C.T. For MMP2 À735 C.T, nine comparisons with 3277 cases and 4379 controls were included. No difference in terms of MMP2 À735T allele frequency between Asian and European populations was observed (Asian: 23.2%, 95% CI 20.6-25.8%; European: 17.5%, 95% CI 27.0-62.0%; P 5 0.0623).
Significant heterogeneity was found in the whole group comparison. Overall, individuals with MMP2 À735 TT and TC genotypes were less susceptible to cancer than those with CC genotype. In lung, oesophageal, Asian, smoking and non-smoking subgroups, positive associations were also found under dominant model. However, no association between MMP2 À735 C.T and Including bladder, hepatocellular, ovarian, cervical and prostate cancer; f including hepatocellular, gastric and ovarian cancer; g including ovarian, cervical, prostate, hepatocellular, breast, head and neck, oesophageal and lung cancer. h One study only provided the genotype distribution in smokers, but no data in non-smokers. i Including hepatocellular, renal, bladder, endometrial, ovarian and uterine cancer. *Statistically significant with P , 0.05; **statistically significant with P 0.001. MMP2, 7 and 9 promoter polymorphisms and cancer risk cancer risk was observed in head and neck or in European subgroups (Table I and Figure 2 ). In the upper aerodigestive tract cancer group, positive association was observed under dominant model and allelic contrast (supplementary Table S3 is available at Mutagenesis Online). The study of Zhai et al. (27) (Table I and  Figure 3 and supplementary Tables S2 and S3 are available at Mutagenesis Online). Sensitive analysis showed that the results of meta-analysis were not materially changed when excluding any individual study. MMP9 À1562 C.T. For MMP9 À1562 C.T, 23 comparisons with 5098 cases and 6442 controls were included in this study. No significant difference in terms of the MMP9 À1562 T allele frequency between two major ethnicities was detected (Asian: 13.5%, 95% CI 11.8-15.2% and European: 15.4%, 95% CI 10.2-20.6%; P 5 0.3101). In the study of Zhai et al. (27) , genotype distribution of control samples deviated from HWE (v 2 5 8.20, P 5 0.004). There was no significant heterogeneity among the 23 comparisons under recessive model, dominant model or allelic contrast. Overall, there was no evidence that MMP9 À1562 C.T was associated with cancer susceptibility under three genetic contrasts. Negative results were also observed in subgroup analyses stratified by tumour site and ethnicity (Table I) . Negative results maintained when further stratifying colorectal cancer and head and neck cancer by ethnicity (supplementary Table S2 is available at Mutagenesis Online). Meta-analysis for the upper aerodigestive tract cancer group also did not show positive association (supplementary Table S3 is available at Mutagenesis Online).
Haplotype analyses
Among the included studies, three studies, which investigated oesophageal cancer, lung cancer and ovarian cancer, provided data on MMP2 À1306 C.T and À735 C.T haplotype distributions (supplementary Table S1 is available at Mutagenesis Online). There were four possible haplotypes derived from the two known variant genotypes: C-1306_C-735, C-1306_T-735, T-1306_C-735 and T-1306_T-735. C-1306_C-735 was the most common haplotype, while T-1306_T-735 was the rarest. The results showed that, compared with C-1306_C-735, each of the other haplotypes was associated with decreased cancer risk (C-1306_T-735 versus C-1306_C-735: OR 5 0.79, 95% CI 0.70-0.90, P , 0.001, P heterogeneity 5 0.313, 
Publication bias
For MMP2 À1306 C.T, Begg's funnel plot and Egger's test provided no evidence of publication bias (TT þ TC versus CC, t 5 À0.11, P 5 0.912). Similarly, there was no evidence of publication bias for MMP2 À735 C.T (TT þ TC versus CC, t 5 0.90, P 5 0.399), MMP7 À181 A.G (GG þ GA versus AA, t 5 1.18, P 5 0.257) and MMP9 À1562 C.T (TT þ TC versus CC, t 5 À0.27, P 5 0.790; Figure 4 ). Begg's funnel plot and Egger's linear regression test were also conducted in subgroups with more than two studies, and no evidence of publication bias was observed (data not shown).
Discussion
SNPs are the most abundant form of genetic variation in the human genome. There are $10 million SNPs in the human genome. It is likely that only a very small percentage of SNPs in the human genome are functionally important, while the vast majority of SNPs are functionally neutral. Several SNPs in MMPs promoter regions have been found to be functional on gene transcription. In our previous study, we analysed the association between two polymorphisms in MMP1, MMP3 promoter region and cancer risk. In this study, the association of other four MMP polymorphisms with cancer risk was analysed (1, 62) .
The MMP2 À1306 C.T transition is located in a core recognition sequence of Sp1 (CCACC box), which abolishes the Sp1-binding site and consequently diminishes promoter activity. 
MMP2, 7 and 9 promoter polymorphisms and cancer risk
Transient transfection experiments showed that reporter gene expression driven by the C allele was significantly greater than reporter gene expression driven by the T allele both in epithelial cells and macrophages (63) . Similarly, the C.T polymorphism located at MMP2 À735 also destroys an Sp1-binding element, with the T allele being associated with significantly diminished promoter activity (25) . Our results of meta-analysis showed that MMP2 À1306 TT and TC genotype carriers were less susceptible to lung, head and neck, gastric and oesophageal cancer compared with CC genotype carriers; MMP2 À735 TT and TC genotype carriers also had a lower lung and oesophageal cancer risk than those with CC genotype. Previous studies have reported that MMP2 is over-expressed in cancers of the above tissues. It is possible that in these tissues, high expression level of MMP2 is a risk factor for cancer development, so MMP2 À1306 T and À735T are associated with a lower cancer risk owing to driving a relatively lower expression of MMP2. Haplotype analyses showed that haplotypes with at least one À1306T or À735T allele were associated with lower cancer susceptibility than the C-1306_C-735 haplotype. However, as the study number and sample size were small, these results should be treated as preliminary. Further study with larger sample size is needed to better evaluate the association between these haplotypes and cancer risk.
For MMP7 À181 A.G, functional analysis in vitro has shown that nuclear proteins bind with higher affinity to the À181 G allele than to the À181 A allele and the promoter activity variation of À181G allele was 2-to 3-fold higher than that of the À181 A allele, which may induce elevation of the MMP7 mRNA transcription and subsequently increase the protein expression (64) . Association between MMP7 À181 A.G and increased cancer risk was found in the gastric cancer subgroup, but not in the colorectal cancer subgroup. Because of the small study number, for eight individual cancers, there was only one study. Positive results of meta-analysis in other tumour subgroups did not mean that MMP7 À181 A.G was associated with each of these cancer types. Further study is needed to better evaluate the real association between MMP7 À181 A.G and individual cancers.
For MMP9 À1562 C.T, transient transfection experiments and DNA-protein interaction assays indicated that the T allele had a higher promoter activity than the C allele, which appeared to be due to preferential binding of a putative transcription repressor protein to the C allelic promoter (65) . Although positive association of MMP9 À1562 C.T with cancer risk existed in some individual studies (9, 31) , the pooled results showed that this genetic variant was not a major risk factor for most cancers. However, as the study did not cover all types of cancer, and environment factors were not considered in this study, whether this polymorphism is associated with a certain type of cancer or can be modified by certain environmental factors should be investigated in a further study. Heterogeneity is a potential problem when interpreting the results of all meta-analyses. In this study, significant heterogeneity was detected in overall comparisons for three of the four polymorphisms. For MMP2 À735 C.T, significant heterogeneity disappeared after excluding one study, while for MMP2 À1306 C.T and MMP7 À181 A.G, heterogeneity was caused by confounding factors. In all, we tested six factors that might contribute to heterogeneity in between studies. Tumour site was one of the causal reasons. Different MMP regulation mechanisms and microenvironment in different tissues may explain why the same polymorphism plays different roles in different types of cancers. Ethnicity was another causal factor. People of different populations have different genetic backgrounds and may be exposed to different environment factors, so the same polymorphism may play different roles in different populations. Control type also contributed to heterogeneity. The results from healthy controls are more reliable than those from diseased controls, as the frequency of MMP alleles in a diseased population may deviate from normal. Gender type was also a causal reason for heterogeneity. In this study, some comparisons were of gynaecological cancers. Unlike other kinds of cancers, the development of gynaecological cancers can be influenced not only by some environmental factors, but also by other factors, such as oestrogen, pregnancy and coitus. Genotyping method and sample size, which could reflect the quality and reliability of individual studies, were also considered in this study. However, they did not provide main sources of heterogeneity.
The present study has some limitations. First, although we have collected all eligible studies, the study number was not large, especially in subgroup meta-analyses. Therefore, some subgroup analyses may not have enough statistical power to explore the association of these polymorphisms with cancer susceptibility, and it is impossible to conduct further stratified analysis in some tumour site subgroups. Second, we could not evaluate the modification effects of drinking and gender factors (not in gynaecological cancers or prostate cancer) because of the limited statistics from individual studies. Third, although we have shown the results for combined cancers, we think that the results in subgroup analyses were more meaningful, as these polymorphisms may play different roles in different tissues among people with different genetic backgrounds. Fourth, significant heterogeneity was detected in some comparisons, which may reduce the credibility of our results. Fifth, only 33 comparisons provided adjusted estimates, and the adjusted covariates varied among these studies, so we could not provide results based on adjusted estimates. In spite of this, our meta-analysis shares some key advantages in several aspects. First, our results were more reliable than the result from a single study, as cases and controls were pooled from different studies, which significantly increased statistical power of the analysis. Second, no publication bias was detected, and the quality of the most case-control studies included in the current meta-analysis was good.
In conclusion, this meta-analysis suggests that MMP2 À1306 C. T is associated with decreased lung, head and neck, gastric and oesophageal cancer risk; MMP2 À735 C.T is associated with decreased lung and oesophageal cancer risk and MMP7 À181 A.G is associated with higher gastric cancer risk. MMP9 À1562 C.T may not be a major risk factor for most types of cancers. Larger scale primary studies should be required to further evaluate gene-gene and gene-environment interactions on these polymorphisms and tissue-specific cancer risk in an ethnically specific population.
Supplementary data
Supplementary Tables S1-S3 are available at Mutagenesis Online. 
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